CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02632708
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:37.217869+00:00
Published At: 2025-04-11T00:00:00+00:00
Record Updated At: 2025-04-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Newly Diagnosed Acute Myeloid Leukemia (AML)", "Untreated AML", "AML Arising From Myelodysplastic Syndrome (MDS)", "AML Arising From Antecedent Hematologic Disorder (AHD)", "AML Arising After Exposure to Genotoxic Injury"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-04-11"
protocolSection.identificationModule.nctId: "NCT02632708"
protocolSection.identificationModule.officialTitle: "A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.